• CAS
  • |
  • C&EN
  • |
  • Journals
  • |
  • ACS

search site
Advanced Search »
  • Home
  • |
  • About CAS
    • 100th Anniversary Celebration
    • CAS Quotes
    • Colors of Chemistry
    • Careers at CAS
    • Contact Us
    • Directions to CAS
    • FAQs
  • |
  • Our Expertise
    • CAS Databases
    • Value Added Tools
    • Technical Service and Support
  • |
  • Solutions
    • Researchers
    • IP Professionals
    • Information Professionals
    • Academics
  • |
  • Products & Services
    • SciFinder
    • SciFinder Scholar
    • STN Family of Products
    • Science IP
    • CAS Client Services
    • CAS Document Detective Service
    • CD Products
    • Print Products
  • |
  • Support & Training
    • SciFinder
    • SciFinder Scholar
    • STN
    • STN Express
    • STN AnaVist
    • STN Viewer
    • STN on the Web
    • STN Easy
    • CAS Customer Care
  • |
  • News & Events
    • What's New
    • Press Room
    • News Releases
    • In the News
    • Trade Shows
  • CAS Science Spotlight Home
  • Most Requested Patent Families 3Q07-Chemistry and Related Science
  • About
  • What's New
Home   •   Spotlight  •  rlist3q07p  •  Most Requested Patent Families 3Q07-Chemistry and Related Science (6)
Most Requested Patent Families 3Q07-Chemistry and Related Science

spotlightlogo.gif

Following is one of the Patent Families most requested by researchers using CAS electronic products.


CAS indexed 866 chemical substances from this document.
CAS subject entries for this document include: Drugs of abuse; Mental and behavioral disorders; Alkynes; and 20 additional concepts.

CAPLUS COPYRIGHT 2007 ACS on STN

 

TITLE: Preparation of heterocycle-containing alkynyl derivatives as modulators of metabotropic glutamate receptors
INVENTOR(S): Bessis, Anne-Sophie; Bolea, Christelle; Bonnet, Beatrice; Epping-Jordan, Mark; Poirier, Nicholas; Poli, Sonia-Maria; Rocher, Jean-Philippe; Thollon, Yves
PATENT ASSIGNEE(S): Addex Pharmaceuticals SA, Switz.
SOURCE: PCT Int. Appl., 308 pp. CODEN: PIXXD2
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
---------------     ----   --------    --------------------   --------
WO 2005123703 A2 20051229 WO 2005-IB2390 20050617 WO 2005123703 A3 20061012 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2005254808 A1 20051229 AU 2005-254808 20050617 CA 2570987 A1 20051229 CA 2005-2570987 20050617 EP 1765795 A2 20070328 EP 2005-766895 20050617 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU CN 101001846 A 20070718 CN 2005-80026025 20050617 IN 2006CN04639 A 20070629 IN 2006-CN4639 20061218 NO 2007000288 A 20070116 NO 2007-288 20070116

ABSTRACT:
The present invention relates to heterocycle-contg. alkynyl derivs. (WC.tplbond.C(CH2)nXW' (I); variables defined below; e.g. 1-methyl-2-[4-(pyridin-2-yl)-3-butynyl]-1H-benzo[d]imidazole (shown as II)) that are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") and are therefore useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. Methods of prepn. are claimed and prepns. and/or characterization data for .apprx.250 examples of I are included. For example, II was prepd. in 4 steps (not stated, 23, 70 and 31 % yields, resp.) starting with chlorination of (1-methyl-1H-benzimidazol-2-yl)methanol to give 2-chloromethyl-1-methyl-1H-benzimidazole, which was coupled with trimethylprop-1-ynylsilane to give 1-methyl-2-[4-(trimethylsilanyl)-3-butynyl]-1H-benzimidazole, which was deprotected to give 2-(3-butynyl)-1-methyl-1H-benzimidazole, which was coupled with 2-iodopyridine to give II. For I: W is a 5-, 6-heterocyclic ring contg. a N adjacent to the ethynyl bond, which ring may optionally be fused with a 5- or 6-membered ring contg. .gtoreq.1 atoms independently C, N, O and S; X = an (un)substituted C1-C6-alkyl, C1-C6-alkylhalo, C2-C6-alkynyl, C2-C6-alkenyl, O-C0-C6-alkyl, O-C1-C6-alkylhalo, O-C3-C6-alkynyl, O-C3-C6-alkenyl, O-C3-C7-cycloalkyl, C1-C6-alkyl-O, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C0-C6-alkyl, et al.; W' = a 5- or 6-membered ring contg. .gtoreq.1 atoms = C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring contg. .gtoreq.1 atoms = C, N, O and S; addnl. details including provisos are given in the claims. Results of a mGluR5 binding assay for >200 examples of I are tabulated; also test results of a marble burying model of anxiety in mice and Vogel conflict drinking model of anxiety in rats are discussed.

Updated 11/5/2007 2:00:57 PM
Home  |  About CAS  |  Our Expertise  |  Solutions  |  Products & Services  |  Support  |  News & Events
Copyright © 2008 American Chemical Society